Summary: DermaSensor is an FDA-cleared, handheld device designed to help clinicians assess the risk of skin cancer in suspicious skin lesions. It uses a combination of optical spectroscopy and artificial intelligence to analyze lesions and provide immediate risk assessment results. This tool aims to enhance clinical confidence, support timely referrals, and improve patient outcomes by offering an objective, non-invasive method for skin cancer evaluation.

Summary: Pantheon™ is an AI-powered pathology platform that offers an integrated solution for slide viewing, reading, and analysis. It is designed to improve the precision, efficiency, and consistency of cancer diagnosis by providing pathologists with advanced tools for identifying, grading, and classifying cancer. The platform supports seamless integration with digital pathology workflows and is compatible with major pathology systems.

Summary: CADDIE is a cloud-based artificial intelligence tool designed to support gastroenterologists during colonoscopy procedures. It integrates seamlessly into clinical workflows, offering features like polyp detection and characterization to assist in real-time decision-making. This technology aims to improve patient outcomes by providing a higher level of diagnostic accuracy and efficiency.

Summary: MAGENTIQ-COLO™ leverages artificial intelligence and machine learning to assist gastroenterologists in detecting polyps during colonoscopies, aiming to increase adenoma detection rates and reduce the miss rate of sessile serrated adenomas. With over 65 million frames processed and validated by a comprehensive study, the tool integrates into gastroenterology clinics to support clinical decision-making and improve the quality of colonoscopy procedures.

Summary: SKOUT by Iterative Health is designed to assist physicians during colorectal cancer screening and surveillance by providing real-time AI analysis. This tool aims to enhance the accuracy and efficiency of screenings, helping in the early detection and monitoring of colorectal cancer. By integrating advanced AI algorithms, SKOUT serves as an additional layer of analysis to support healthcare professionals in making more informed decisions.

Summary: Guardant Health offers a range of blood tests designed to provide critical insights for cancer care. These tests, including the Shield™ Blood Test, Guardant Complete®, and Guardant Infinity™, are used for cancer screening, as well as for guiding treatment decisions in patients with early and advanced-stage cancer. By analyzing circulating tumor DNA, Guardant Health's tests aim to improve clinical outcomes through precision oncology.

Summary: WRDensity leverages artificial intelligence to provide a more consistent assessment of breast density during mammography screenings. It is designed to integrate seamlessly with RIS/PACS systems and has been trained on over 600,000 images from the Mallinckrodt Institute of Radiology. This tool aims to create uniformity in density assessment at the practice level, improving the accuracy of breast cancer screenings.

Summary: Koios DS™ leverages artificial intelligence and machine learning to provide clinical decision support for the diagnosis of breast and thyroid cancer through ultrasound imaging. This software aims to improve diagnostic accuracy and efficiency, potentially leading to earlier detection and treatment. With FDA clearance and CE marking, Koios DS™ integrates into clinical workflows, offering a billable procedure that enhances both survival rates and workflow efficiency.

Summary: DERM (Deep Ensemble for the Recognition of Malignancy) is a Class III CE marked AI as a Medical Device (AIaMD) designed to improve skin cancer triage. It integrates with teledermatology platforms to accurately triage patients with non-cancerous lesions away from cancer pathways, optimizing dermatologist capacity for the most needed cases. This technology aims to enhance patient outcomes by ensuring timely and accurate skin cancer care.

Summary: AssureMDx is a urine-based test designed to help physicians identify patients with hematuria who are at increased risk for bladder cancer, facilitating timely referral to urology for further clinical evaluation. The test evaluates genomic changes associated with bladder cancer, including DNA methylation status and somatic mutation status of specific genes, to stratify patients by risk and potentially avoid unnecessary invasive procedures for those at low risk.

Summary: QVCAD is an advanced AI software tool developed by QView Medical, Inc., specifically designed to improve the detection of breast cancer in women with dense breast tissue through the analysis of 3D Automated Breast Ultrasound (ABUS) images. It serves as a computer-aided detection (CAD) system that assists radiologists by highlighting areas of concern in ultrasound images, thereby facilitating a more efficient and accurate review process.

Summary: DELFI Diagnostics utilizes a novel approach in cancer detection by analyzing cell-free DNA fragments in the bloodstream with advanced machine learning and next-generation sequencing technologies. This method, known as fragmentomics, is designed to support early-stage cancer detection by scanning millions of data points to identify cancer-associated DNA fragments. This scalable approach aims to improve upon existing liquid biopsy methods by detecting previously unrecognized patterns associated with cancer.

Summary: Simoa Technology by Quanterix is designed to enable the detection of biomarkers at levels previously undetectable in blood and other sample types. This technology supports a wide range of research and diagnostic applications across various therapeutic areas such as neurology, oncology, cardiology, immunology, and infectious disease. Its high sensitivity and precision make it a valuable tool for early disease detection, prognosis, and monitoring treatment efficacy.

Summary: Singlera Genomics specializes in liquid biopsy and cancer early detection technologies, offering a wide range of products for cancer early screening, diagnosis, and prognostic monitoring. Their focus on methylation detection technology aids in the risk assessment, early screening, medication guidance, and recurrence monitoring of various high-incidence cancers. With a commitment to innovation and collaboration, Singlera Genomics is a key player in the global effort to advance cancer diagnostics.

Summary: Flare Therapeutics is focused on the discovery and development of small molecule drugs aimed at regaining transcriptional control hijacked by cancer. Their research targets transcription factors, a previously elusive area in drug discovery, with the goal of changing the trajectory of cancer treatment through precision oncology.

Summary: Signatera is a highly sensitive, personalized MRD test that detects circulating tumor DNA (ctDNA) in the blood. It is tailored to the unique genetic makeup of an individual's tumor, allowing for the early detection of cancer recurrence and the monitoring of treatment response. This non-invasive test offers a way to identify minimal residual disease with high precision, providing valuable insights for personalized treatment planning.

Summary: Onc.AI utilizes a comprehensive oncology dataset, including diagnostic imaging, EMR, labs, and genomics, to develop AI models aimed at advancing precision oncology. Their initial focus is on predicting clinical outcomes in metastatic lung cancer, supporting both pharmaceutical clinical development and medical oncologist decision-making. The technology is designed to integrate seamlessly into existing clinical workflows, providing actionable insights to inform treatment strategies.

Summary: Stratipath Breast is an AI-powered tool designed for the prognostic risk profiling of breast cancer, capable of identifying patients with varying risks of disease progression. It analyzes cancer tissue to provide insights into the likelihood of disease advancement, offering a quicker and less costly alternative to gene expression testing. This tool is integrated into clinical workflows, providing results that can significantly impact treatment decisions.

Summary: SmartMammo™ integrates into existing breast cancer diagnostic workflows to improve both diagnostic accuracy and workflow efficiency. Utilizing the cloud-native DeepHealth OS, it ensures seamless interoperability with current systems, aiming to streamline the diagnostic process. The tool is designed to prioritize mammograms likely to have cancer, drawing attention to key image areas and potentially raising general radiologists' detection rates to specialist levels.

Summary: MammoScreen by Therapixel utilizes artificial intelligence to analyze mammography images, aiming to improve the accuracy and efficiency of breast cancer detection. This technology supports radiologists by identifying and highlighting areas of concern within mammograms, potentially speeding up diagnosis and treatment planning. Its adoption by healthcare providers like the Mayo Clinic underscores its effectiveness in clinical settings.